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| INTRODUC TI ON
Pancreatic cancer (PC) is one of the most aggressive malignancies. 1 In 2018, there were 44 330 estimated patients with PC-related death in the USA and 34 990 patients in Japan, suggesting that PC is the fourth leading cause of cancer-related death in both countries. 1, 2 In the National Comprehensive Cancer Network (NCCN) guidelines, 3 resectability is categorized as resectable (R), borderline resectable (BR), or unresectable (UR) based on multidetector computed tomography (MDCT) evaluation. Upfront surgery followed by postoperative adjuvant therapy was generally recommended for potentially resectable PC (R-PC) 3, 4 as well as neoadjuvant treatment followed by surgery for BR-PC in order to achieve R0 resection. 3 Despite marked improvements in diagnostic modalities, PC often presents as a systemic disease, which precludes early detection.
More than 80% of patients are diagnosed with UR because of its high metastatic (M) potential. 5 Recent advances in anticancer treatment for locally advanced (LA) UR, or M-PC facilitate good disease control; such patients sometimes convert to surgical resection. 6 This surgical strategy is called conversion surgery (CS). 7 Several reports on CS in patients with UR-PC have shown that it has a favorable effect on overall survival (OS). 6, 8, 9 In recent meta-analyses of reports from 2009 to 2015, the rate of conversion from UR-LA-PC to surgery was 26% and OS ranged from 18.7 to 24.2 months. 10, 11 The entire cohort examined in these meta-analyses comprised patients recruited into clinical trials conducted before 2013.
The Hokkaido Pancreatic Cancer Study Group (HOPS) conducted multicenter phase II studies to investigate the efficacy of neoadjuvant treatment for BR-PC and R-PC. To analyze the data from patients with UR-PC whose diagnosis was based on central review of MDCT findings but were ineligible for these two HOPS studies, we conducted a multicenter study. Since those patients were managed at referral hospitals in Hokkaido prefecture thereafter, their survival data were recognized as real-world patient outcomes.
| ME THODS

| Study design
In this multicenter, retrospective study by HOPS, we assessed the outcomes of patients clinically diagnosed with UR-PC and treated at tertiary referral hospitals around Hokkaido prefecture. The institutional review boards of Sapporo Medical University Hospital (282-39, University Hospital Medical Information Network Clinical Trials Registry, UMIN000035454) and each participating hospital approved the study protocol.
| Patients
Hokkaido Pancreatic Cancer Study Group conducted two multicenter phase II studies to investigate the efficacy of neoadjuvant treatment for R-PC and BR-PC (UMIN 000013031/000012293). They involved neoadjuvant chemotherapy (CT) consisting of two cycles of S-1 (80 mg/m 2 , twice daily) or neoadjuvant chemoradiotherapy (CRT) with a total dose of 50. 
| Assessment
Clinical treatment effect was assessed using RECIST version 1.1.
13
The histologic assessment of the extent of preoperative treatment response was evaluated using the Evans grading system. 14 The
Clavien-Dindo classification was used to assess postoperative complications. 15 Mortality was defined as death during the hospital stay when surgery was performed. Individual survival was defined as the duration between the date of treatment initiation and death or latest hospital visit. Median follow-up was defined as the duration be- 
| Outcome measures and statistical analysis
| RE SULTS
| Patient characteristics
Among 247 patients intended to be recruited for HOPS phase II studies from October 2013 to April 2016, 88 and 93 patients were considered to have R-PC and BR-PC, respectively. The remaining 66
patients, all of whom were confirmed to have UR-PC initially, were enrolled in this cohort (Table 1) 
| Treatments
Induction abine plus nab-paclitaxel therapy was adopted at a lower rate (20%) compared to the overall adoption rate for first-and second-line therapies (52.6%; P = 0.052), suggesting treatment toxicity (Figure 1 ).
| Conversion to radical surgery and surgical outcomes
Surgery was not recommended for 51 of 66 patients with UR-PC.
Median progression-free survival in these patients was estimated to be 5.7 months (95% confident interval [CI], 4.7-6.8). Twenty-one patients (12 with UR-LA and nine with UR-M disease) had disease control for more than 6 months. Fifteen patients developed progressive disease and six patients continued to have PR or SD for 11.8-44.8 months until the latest follow-up. The reasons why surgery was not recommended for these six patients included persistent liver metastasis in two patients, persistent ascites in one patient, and plexus involvement in three patients that extended into the superior mesenteric (n = 2) and common hepatic arteries (n = 1).
Radical surgery was performed in the remaining 15 patients (12 patients with UR-LA disease and three with UR-M disease; Figure 1) but completed in 12 (10 patients with UR-LA disease and two patients with UR-M disease; Table 2 ). Three patients with metastasis at the time of surgery underwent palliative procedures that included probe laparotomy, choledochojejunostomy, and laparoscopic gastrojejunostomy. The median preceding treatment interval was Table S1 .
| Predictors for conversion
Among background patient characteristics, various clinicopathologic parameters, and treatment history, none were identified as significant predictors of conversion (Table S2) . Interestingly, patients with CS had neither nodal nor peritoneal metastasis on initial imaging (Table S1 ).
| Oncological outcome
As of the latest follow-up, 51 (77.3%) of 66 patients had died, includ- Median duration from initial treatment to initial recurrence was estimated to be 29.0 months (range, 10.3-37.3; Figure 2B , Table 3 ).
The initial sites of recurrence included the liver (n = 2), peritoneum (n = 2), remnant pancreas (n = 2), lung (n = 1), and lymph node (n = 1; F I G U R E 1 Treatment line and regimen by reason for unresectability. †P value for statistical trend in the distribution of treatment modalities (in the upper panel) and ‡ of chemotherapeutic regimens (in the lower panel) for each group. Data are presented as number of patients, %. AI, arterial infusion chemotherapy; CRT, chemoradiotherapy; CS, conversion surgery; CT, chemotherapy; FFX, FOLFIRINOX; Gem, gemcitabine; GnP, gemcitabine plus nab-paclitaxel; GS, gemcitabine plus S-1; NA, data not available; PTX, paclitaxel. TT, thermal therapy Table 3 ). Metastasectomy was performed in patients who initially recurred in the remnant pancreas (remnant distal pancreatectomy, n = 2) and lung (partial pneumonectomy, n = 1). Those three patients were all alive without additional recurrences at the latest follow-up for 11.7, 13.1, and 4.7 months after metastasectomy, respectively. CI, 0.017-0.348; P = 0.001) was a significant predictor of longer OS, and ascites on diagnostic imaging was a marginal predictor of shorter OS (HR, 2.192; 95% CI, 0.967-4.969; P = 0.060; Table 4 ). Subgroup analyses showed that survival of patients with ascites on diagnostic imaging was significantly worse compared with patients without this finding (MS, 10.2 vs 20.6 months; log-rank P = 0.026; Figure 3A ).
Modern chemotherapeutic regimens such as FOLFIRINOX or gemcitabine plus nab-paclitaxel as second-line treatment had comparable survival (MS, 16.7 vs 22.2 months; log-rank P = 0.9482; Figure 3B ).
However, patients with CRT as second-line treatment had significantly better MS than those without (24.2 vs 14.5 months; log-rank P = 0.046; Figure 3C ). It is obvious that there was bias in treatment selection because CRT as second-line treatment was used in eight (75%) of 12 patients who underwent CS, compared with 15 (27.8%) of 54 cases who did not undergo CS (P = 0.0265). In terms of treatment response, no association between histopathological tumor response (Evans ≥III vs <III) and prognosis of patients with UR-PC was observed (log-rank P = 0.112, data not shown). Several studies on CS among patients with UR-PC have been reported so far. 6, 8, 9, 11, [17] [18] [19] [20] [21] In the most recent meta-analysis based on reports since 2009, the rate of conversion from UR-LA disease to surgery was 26% and OS was 18.7 months. 10 Other reports of conversion from initial UR-PC to radical surgery after favorable response to induction treatment reported a wide range of conversion rates, depending on whether patients with M disease were included. In the current study cohort, postoperative recurrence occurred in more than half of patients with a median duration from CS to initial recurrence of 18.7 months, although the R0 resection rate was 91.6% with pathological Evans grades III-IV disease in four patients.
| D ISCUSS I ON
Some patients had earlier recurrence after CS. Peritoneal metastasis occurred the earliest, with a median time to relapse after CS of 5.4 months. For patients with early postoperative recurrence within 18 months, corresponding to the median OS with the current nonsurgical cohort, highly invasive CS cannot be considered an effective treatment. Further studies including genomic or molecular approaches are necessary, as well as liquid biopsy to detect latent distant metastasis. 24, 25 These efforts might facilitate identifying patients at higher risk for early disease relapse after surgical resection and lead to treatment decisions for more intensive therapies to eliminate subclinical, residual, and latent disease in patients with initial UR-PC after induction treatment.
Whether to convert from initial chemo(radio)therapy to surgery solely on the basis of radiological examination remains controversial. Several authors have documented a significant association between preoperative CA19-9 values and sub-radiographic, UR-PC with systemic metastases. 8, 26, 27 The CA19-9 response to neoadjuvant therapy has been reported to be another potential marker for R0 resection, histopathologic response, and survival, 26 suggesting that CA19-9 levels should be taken into account when evaluating the efficacy of CT. 18 F-fluorodeoxyglucose PET findings could also be a potential indication for CS in patients with primary UR-LA-PC,
TA B L E 3 Details about the seven patients with postoperative recurrence
Site of initial recurrence (n = 7) n (%)
Period from CS to relapse, months, median (range) and may help in selecting patients who qualify for complete surgical resection with a promising prognosis. 27 Future studies should assess how to select patients for CS and whether CS after initial induction treatment improves OS.
This current study has some limitations. It was a retrospective study with a small number of patients who underwent CS. There was likely some bias in the selection of CT regimens due to the concomitant HOPS-BR01 study involving second-line gemcitabine monotherapy, suggesting possible inconsistencies in decision-making with regards to subsequent treatment lines or indications for surgery. Decision-making at the discretion of the attending physician for each patient was the major reason why an analysis of the best timing for surgical conversion could not be performed. The predictors of conversion were not determined, perhaps because the series of treatments was not systematically determined. In our hospital, decision-making has been largely standardized based on multimodal treatment conferences since 2012. 9 Another limitation of this study is that initial PC status was evaluated with only MDCT and that neither tumor markers such as CA19-9 nor staging laparoscopy were performed. It was not possible to evaluate changes in tumor markers objectively in relation to treatment effect or prognosis since the CA19-9 measurement protocol was not standardized between participating hospitals. Comprehensive treatment evaluation with tumor markers plus diagnostic imaging might more accurately predict the timing to surgical conversion or prognosis. Staging laparoscopy allows for the diagnosis of minute distant organ metastasis 28 but was not performed in this cohort, suggesting overestimation of suspected peritoneal metastasis or undetected latent distant metastasis in UR-LA-PC. Recently, international consensus on the definition and criteria for BR-PC was defined according to three distinct dimensions: anatomical, biological, and conditional. 29 This definition acknowledges that resectability is not just about the anatomic relationship between the tumor and vessels, but that biological and conditional dimensions including the status of the tumor marker CA19-9 (> or ≤500 units/mL) and performance status are also important. In order to improve OS, future studies should assess whether to consider CS after initial induction treatment for patients with initial UR-PC and its timing. In Japan, the PREP-04 trial (UMIN 000017793), a multi-institutional prospective observational study to investigate the effects of CS in patients with initial UR-PC, is already ongoing.
| CON CLUS ION
Conversion surgery following a favorable response to sequential treatment may be a good option to prolong survival in patients with UR-PC. Precise imaging diagnosis based on MDCT followed by sequential multimodal anticancer treatment is essential.
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